NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-MH-21-250 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-21-019 from the NIH Guide for Grants and Contracts. Research funded by this initiative will examine the effects of radiation exposure on the immune system and explore possible treatments for radiation-induced immune dysfunction. Research gaps exist in understanding the mechanisms of injury and repair with regard to radiation-induced immune system dysfunction, and these gaps must be addressed to better develop MCMs for radiation exposure. Through this initiative, the NIAID Radiation and Nuclear Countermeasures Program (RNCP) will support development of animal models for immune-targeted radiation injuries, studies to better understand radiation impacts on the immune system (including immune system-mediated multi-organ injury), identification of immune-specific pathways targeted by radiation, as well as biomarkers of exposure and mitigators/treatments that target immune-related radiation response pathways.
Funding Opportunity RFA-DA-22-002 from the NIH Guide for Grants and Contracts. The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse. These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigatorinitiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse. NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff.
Notice NOT-NS-21-052 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-099 from the NIH Guide for Grants and Contracts
Notice NOT-NS-21-051 from the NIH Guide for Grants and Contracts
Notice NOT-NS-21-055 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-102 from the NIH Guide for Grants and Contracts
Notice NOT-AI-21-047 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-096 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-21-197 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials.
Funding Opportunity PAR-21-211 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-431. NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01 currently TEMP-11234.
Funding Opportunity PAR-21-210 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-430. NIMH seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This FOA encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support effectiveness trials testing post-acute phase interventions that are statistically powered to provide a definitive answer regarding the study intervention's effectiveness. Support for pilot effectiveness trials to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches is provided via a companion R34 (Currently TEMP-11235)
Funding Opportunity RFA-RM-21-012 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDGs Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches. Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins.
Funding Opportunity PAR-21-185 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Mentoring Activities
Notice NOT-DA-21-042 from the NIH Guide for Grants and Contracts
Notice NOT-HD-21-024 from the NIH Guide for Grants and Contracts
Notice NOT-RM-21-019 from the NIH Guide for Grants and Contracts
Notice NOT-OD-21-098 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-21-214 from the NIH Guide for Grants and Contracts. Provide short-term training experiences to faculty members from diverse backgrounds that would result in strengthening their ability to perform independent research in genomics. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.